Meeting
2020 ASCO Virtual Scientific Program
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
Authors
Evan Y. Yu
University of Washington, Seattle, WA
Evan Y. Yu , David Laidley , Frederic Pouliot , Stephan Probst , Robert Sabbagh , Giuseppe Esposito , Fred Saad , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03939689
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5596)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5596
Abstract #
TPS5596
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: Evan Y. Yu
Poster
2021 Genitourinary Cancers Symposium
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: A. Oliver Sartor
Poster
2022 ASCO Annual Meeting
![CCTG PR21: A randomized phase II study of [<sup>177</sup>lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).](https://d201v5jt9ylckg.cloudfront.net/288/14370/213296/213296_A1829_poster_pv.jpg)
CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
First Author: Kim N. Chi
Poster
2020 ASCO Virtual Scientific Program
CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith